



Onco

Phoenix Life

Product Description

Phoenix Onco includes 2 different formulas, Daytime and Nighttime. The Daytime is designed to actively reduce inflammation, slow/stop metastasis and reduce the size of tumors. The Nighttime is designed to affect apoptosis on cancer cells, while providing relaxation and sleep function and increased appetite.

Cannabinoid Extract Proprietor Compound

A) CANNABIDIOL (CBD), TETRAHYDRACANNABINOL (THC) AND OTHER TRACE CANNABINOIDS A-HUMULENE , B-CARYOPHYLLENE , B-MYRCENE, LINALOOL , P-CYMENE, A-PINENE, B-PINENE
 B) TETRAHYDRACANNABINOL (THC) CANNABINOL (CBN), AND OTHER TRACE CANNABINOIDS A-PINENE, B-MYRCENE, B-PINENE, NEROLIDOL, OCIMENE

Other Ingredients

Medium-chain triglycerides (MCT) derived from coconut, Water, Glycerin, Cannabis Extracts, Kolliphor HS-15, Peppermint Oil.

Global Distribution Strategy

Phoenix Onco is classified as a specific formulation and dosing product that may be exempted or scheduled under a specific country regulations governing pharmaceuticals and drug control. The product must be produced, distributed and sold through licensed medical cannabis facilities and pharmaceutical distribution licensed to handle tetrahydrocannabinol. Distribution will be from Vanuatu and state to state US manufacturing.

Online
This product is classified as containing high amounts of "THC from Cannabis" and therefore can only be sold through licensed agencies. Phoenix Onco Online ordering a provides for pick-up from a licensed distributor. Sold as Phoenix Onco (LE), without specific medical claims within the jurisdictions offered, unless otherwise approved.

Australia
Partner with local licensed producer for distribution under medical cannabis laws. Local clinical trials to be completed in 2022.

Europe
Partner with local licensed distributor under medical cannabis laws. Local clinical trials to be completed in 2023.

Global Distribution
Now that 47 countries have legalized medical cannabis, the inter-country trade is starting to expand. Phoenix Life is focused on import and export of its products from company owned and partnered production facilities. Phoenix Onco can only be sold through licensed agencies through local production and export to over 40 countries.

United States
State to state distribution under product licensing agreement with Equaliti. Clinical trials to be commenced late 2023.

Vanuatu
May be supplied under Dr Approval. Local Supply expected in 2022.

Medical History and Development Information

Initial data review showed positive evidence in the use of cannabis in the treatment of various cancer types. Data gathered from research partners created the two part formulation, leveraging the differing effects. Patient data available on renal cell carcinoma. The product is designed to be sold in Soft Gel Capsules and Sub-lingual Sprays.

Clinical Stage

INITIAL CANDIDATE STRAIN / FORMULATION SELECTED
EFFICACY DATA COLLABORATED WITH RESEARCH TEAM
INITIAL PATIENT GROUP SUCCESS
LARGER PATIENT GROUP SUCCESS
FORMALIZED CLINICAL TRIALS
APPROVED FOR SALE IN LOCAL MARKET
EXEMPTION AVAILABLE FOR IMMEDIATE SALES

LEGEND Completed Next Step Not Completed

Medical Evidence, Citations and other References

US National Library of Medicine - a part of the National Institutes of Health details the following study and abstract More details are available at <https://pubmed.ncbi.nlm.nih.gov/32708138/>
 2020 Jul 21;12(7):1985. DOI: 10.3390/cancers12071985 PMID: 32708138 PMCID: PMC7409346

Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis

Author(s): Andrea M Tomko, Erin G Whynot, Lee D Ellis, Denis J Dupré

Abstract: In recent years, and even more since its legalization in several jurisdictions, cannabis and the endocannabinoid system have received an increasing amount of interest related to their potential exploitation in clinical settings. Cannabinoids have been suggested and shown to be effective in the treatment of various conditions. In cancer, the endocannabinoid system is altered in numerous types of tumours and can relate to cancer prognosis and disease outcome. Additionally, cannabinoids display anticancer effects in several models by suppressing the proliferation, migration and/or invasion of cancer cells, as well as tumour angiogenesis. However, the therapeutic use of cannabinoids is currently limited to the treatment of symptoms and pain associated with chemotherapy, while their potential use as cytotoxic drugs in chemotherapy still requires validation in patients. Along with cannabinoids, cannabis contains several other compounds that have also been shown to exert anti-tumorigenic actions. The potential anti-cancer effects of cannabinoids, terpenes and flavonoids, present in cannabis, are explored in this literature review.